论文部分内容阅读
目的:观察研究血塞通治疗脑卒中早期的临床效果及安全性。方法:选取2014年1月~2015年5月我科室收治疗的诊断为脑卒中的患者80例,按随机数字表法分为观察组和对照组各40例。观察组在对照组的基础上给以血塞通针治疗,对照组给以辛伐他汀基础治疗,分析治疗结束后两组患者血清SOD水平、血清MDA水平、NIHSS评分状况。结果:治疗1周、2周后观察组血清SOD水平分别为(89.94±13.01、98.27±15.86)u/ml,均优于对照组的(73.80±11.25、80.19±12.00)u/ml,且差异具有显著性p<0.05。治疗1周、2周后观察组血清MDA水平分别为(5.16±0.83、3.92±0.51)nmol/ml,均优于对照组的(6.85±1.27、5.16±0.73),且差异具有显著性(p<0.05)。3治疗后观察组高密度脂蛋白胆固醇HDLC和载脂蛋白APROA值分别为(1.34±0.22、1.54±0.14)mmol/L,均优于对照组(0.90±0.23、1.35±0.15)mmol/L,且差异具有显著性(p<0.05)。4治疗1周、2周后,观察组NIHSS评分分别为(11.26±1.40、7.29±1.14),均优于对照组的(14.39±1.85、9.96±1.62),且差异具有显著性(p<0.05)。5观察组患者总有效率达90.0%,明显高于对照组75.0%,且差异有显著性(p<0.05)。结论:血塞通针治疗卒中早期的临床效果确切且与常规对症治疗相比,两者副反应无明显差异。联合用药方案优于常规治疗,值得临床进一步深入研究和推广。
Objective: To observe the clinical effect and safety of Xuesaitong in the early stage of stroke. Methods: From January 2014 to May 2015, 80 patients diagnosed as stroke in our department were randomly divided into observation group (40 cases) and control group (40 cases). The observation group was treated with Xuesaitongzhen on the basis of the control group. The control group was treated with simvastatin. The levels of SOD, serum MDA and NIHSS in the two groups were analyzed after the treatment. Results: The levels of serum SOD in the observation group were (89.94 ± 13.01,98.27 ± 15.86) u / ml after treatment for 1 week and 2 weeks, respectively, which were better than those in the control group (73.80 ± 11.25, 80.19 ± 12.00) u / ml, Significant p <0.05. The levels of serum MDA in the observation group were (5.16 ± 0.83, 3.92 ± 0.51) nmol / ml after 1 week and 2 weeks respectively, which were all better than those in the control group (6.85 ± 1.27,5.16 ± 0.73), and the difference was significant <0.05). 3 After treatment, HDLC and APROA of apolipoproteins in observation group were (1.34 ± 0.22,1.54 ± 0.14) mmol / L, which were significantly higher than those in control group (0.90 ± 0.23,1.35 ± 0.15) mmol / L, And the difference was significant (p <0.05). The NIHSS scores of the observation group were (11.26 ± 1.40, 7.29 ± 1.14), respectively, which were all better than those of the control group (14.39 ± 1.85,9.96 ± 1.62) after 1 week and 2 weeks of treatment, and the difference was significant (p <0.05 ). The total effective rate of observation group was 90.0%, which was significantly higher than that of the control group (75.0%) (P <0.05). Conclusion: Xuesaitong injection is effective in the early stage of stroke and there is no significant difference in the side effects between the two methods when compared with the conventional symptomatic treatment. Combination regimens than conventional treatment, it is worth further study and promotion of clinical.